Following an inter-partes review brought by Mylan against two patents protecting Teva Pharmaceutical Industries’ Copaxone, a drug for treating multiple sclerosis, the US Patent Trial and Appeal Board (PTAB) has invalidated all claims of the ‘250 and ‘413 patents for double-dose 40 mg Copaxone (glatiramer acetate injection) multiple sclerosis treatment. However, on 24 August 2016, TEVA announced that it plans to appeal to the US Court of Appeals for the Federal Circuit.
Erez Vigodman, president and CEO of Teva, said: “We remain confident in the strength of our intellectual property surrounding Copaxone.”
“We are prepared to defend the full suite of our intellectual property through the PTAB and US courts regardless of the time required.”
“We believe patients, physicians and payers will continue to value the efficacy, safety and tolerability of Copaxone and that it will remain a proprietary, global market-leading product for the reduction of relapses in RRMS patients.”
Teva have also announced that the PTAB had declined a request for a post-grant review on an additional Copaxone patent.
Copaxone represents 20% of TEVA’s income and the invalidation sent shares plummeting by 3%.
Categories: cancellation proceedings, claims, drugs, Intellectual Property, Israel IP, Israel Patent, patentable subject matter, Patents, pharmaceuticals, pharmaceuticals and Biotechnology, Teva, Uncategorized, US, US Patent Office, USPTO, פטנט, פטנטים, קניין רוחני, קנין רוחני